SHR 1905
Alternative Names: AIO-001; GSK-5784283; SHR-1905Latest Information Update: 21 Apr 2025
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Atridia; GSK; Jiangsu Hengrui Medicine Co.; Shanghai Hengrui Pharmaceutical
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; Rhinosinusitis
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 04 Mar 2025 Phase-II clinical trials in Asthma (Treatment-experienced) in USA (SC) (NCT06748053) (EudraCT2024-518321-15)
- 23 Jan 2025 Phase-II clinical trials in Asthma (In adolescents) in China (SC) (NCT06786455)
- 31 Dec 2024 Phase-I clinical trials in Chronic obstructive pulmonary disease (Parenteral) before December 2024 (Jiangsu Hengrui Medicine pipeline, December 2024)